抗CD20抗体对难治性无巨核细胞性血小板减少症患者有效，随访25个月
Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up.
作者信息
Mirzania Mehrzad, Khalili Sedigheh, Hasanpoor Akbar, Shamshiri Ahmad Reza
机构信息
Imam Khomini Hospital Complex, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Arak University of Medical Sciences, Arak, Iran.
出版信息
Int J Hematol Oncol Stem Cell Res. 2014;8(2):41-4.
Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to absent of megakaryocytes in the bone marrow. The patient did not respond to intravenous immunoglobulin, cyclosporine or high dose prednisone. After the treatment with anti-CD20 antibody (Rituximab), the patient's clinical symptoms and platelet counts improved.
无巨核细胞性血小板减少症（AMT）是获得性血小板减少症的一种罕见病因。AMT的发病机制和治疗方法尚不清楚。在此，我们报告一名50岁男性，表现为严重血小板减少（7000个血小板/微升）的临床症状，骨髓中巨核细胞明显减少至缺如。该患者对静脉注射免疫球蛋白、环孢素或大剂量泼尼松均无反应。在用抗CD20抗体（利妥昔单抗）治疗后，患者的临床症状和血小板计数有所改善。
Zotero 插件